Investment in Chelsea Therapeutics (NASDAQ:CHTP) presents a very asymmetric risk/return opportunity. On 7th of May, the company announced a merger agreement and going private transaction with Lundbeck (OTCPK:HLUYY). CHTP investors will be receiving $6.44/share in cash (vs. current price of $6.54/share) plus contingent value rights that could result in payments of $1.5/share during the next three years. So the investment thesis boils down to paying $0.1 for a possibility to receive $1.5/share in the future. Thus, this transaction not only provides material potential upside for existing Chelsea Therapeutics' shareholders, but also gives a floor/downside protection just below the current share price.
Details of the merger agreement
Chelsea Therapeutics is a pharmaceutical company that recently...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|